Reviva Pharmaceuticals (NASDAQ:RVPH) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Reviva Pharmaceuticals (NASDAQ:RVPH) posted its earnings results on Monday. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07, Zacks reports.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ:RVPH opened at $0.95 on Tuesday. The stock has a market capitalization of $31.90 million, a PE ratio of -0.86 and a beta of -0.09. The company’s 50-day moving average price is $1.51 and its two-hundred day moving average price is $1.47. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $4.28.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a report on Friday, January 10th. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. Roth Mkm initiated coverage on Reviva Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $7.00 price target on the stock. Finally, HC Wainwright decreased their price objective on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Reviva Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $11.40.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.